Are Analysts Bullish Curis, Inc. (NASDAQ:CRIS) After Last Week?

April 17, 2018 - By Graig Alexander

Curis, Inc. (NASDAQ:CRIS) LogoInvestors sentiment increased to 1.59 in 2017 Q4. Its up 0.11, from 1.48 in 2017Q3. It is positive, as 6 investors sold Curis, Inc. shares while 21 reduced holdings. 14 funds opened positions while 29 raised stakes. 75.55 million shares or 1.01% less from 76.32 million shares in 2017Q3 were reported.
470,799 were reported by Deutsche National Bank Ag. Bridgeway Cap Management accumulated 380,660 shares. D E Shaw Company, a New York-based fund reported 869,923 shares. California-based Schwab Charles Inv Management has invested 0% in Curis, Inc. (NASDAQ:CRIS). Thrivent Financial For Lutherans holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 153,708 shares. The Massachusetts-based Fmr Limited Liability Com has invested 0% in Curis, Inc. (NASDAQ:CRIS). State Street owns 1.88 million shares or 0% of their US portfolio. Mackenzie Corporation accumulated 29,888 shares. California Pub Employees Retirement System has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 210,300 shares. Drw Securities Ltd has 50,000 shares for 0% of their portfolio. Meridian Invest Counsel holds 0% or 10,000 shares in its portfolio. California State Teachers Retirement reported 208,456 shares or 0% of all its holdings. Tower Rech Ltd Liability (Trc) holds 16,820 shares or 0% of its portfolio. Raymond James holds 11,060 shares. Janney Montgomery Scott Limited Liability Company owns 92,600 shares.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 2 analysts covering Curis Inc (NASDAQ:CRIS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Curis Inc had 2 analyst reports since October 23, 2017 according to SRatingsIntel. The firm has “Buy” rating by Guggenheim given on Monday, October 23. Below is a list of Curis, Inc. (NASDAQ:CRIS) latest ratings and price target changes.

06/12/2017 Broker: Cowen & Co Rating: Buy
23/10/2017 Broker: Guggenheim Rating: Buy New Target: $7.0 Initiate

The stock increased 5.17% or $0.0312 during the last trading session, reaching $0.635. About 858,361 shares traded. Curis, Inc. (NASDAQ:CRIS) has declined 76.80% since April 17, 2017 and is downtrending. It has underperformed by 88.35% the S&P500.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $105.17 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Curis, Inc. (NASDAQ:CRIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.